AZNCF News and Press, AstraZeneca Plc From 07/27/20

2020 has been a crazy year. We have experienced an unprecedented money flow into growth/tech stocks , disfavoring value stocks (stocks which are trading below their fundamentals based on their earnings and/or dividends). In fact, the Nasdaq ( QQQ ) is up ~18% year-to-date compared to a decl...

Investment Thesis The much-awaited peer-reviewed data of mRNA-1273, the COVID-19 vaccine candidate of Moderna, Inc. ( MRNA ), has left many questions unanswered. Though the vaccine has been safe and produced neutralizing antibodies, the Phase 3 trial will look for the vaccine's clinical ef...

Quick Take AlloVir ( ALVR ) intends to raise $251 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is a mid stage firm developing drug treatments for virus conditions. ALVR is preparing to enter Phase 3 trials and has an e...

Quick Take iTeos Therapeutics ( ITOS ) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a range of treatments for various cancers, including solid tumors. ITOS is pursuing treatments for...

Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Quick Take AlloVir ( ALVR ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is a mid-stage clinical biopharma firm developing treatments for various virus infections. ALVR is seeking funding to advance its lead cand...

Many investors dumped BELLUS Health ( BLU ) because the company's Phase 2 trial did not offer good results. They appear to forget that BELLUS Health is planning to execute Phase 2b results. If the results are a bit better, the share price will most likely creep up. Besides, the company is targ...

Quick Take ALX Oncology ( ALXO ) intends to raise $128 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for various blood and solid tumor cancer conditions. ALXO is pursuing treatments in...

Mortality defines the human condition. - Drew Gilpin Faust Investor interest in the biotech industry will likely endure for a long time If you're part of my Lead-Lag report-reading cohort, you'll know that I've been providing regular updates on the developments and the performance of o...

Quick Take iTeos Therapeutics ( ITOS ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma firm advancing a pipeline of immuno-oncology drug candidates for treating solid tumors and other can...